| CLH | Chronic Lobular Hepatitis |
|---|---|
| CLH | chronic lobular hepatitis; cleft limb-heart [syndrome]; corpus luteum hormone; cutaneous lymphoid hy... |
| LCIS | lobular carcinoma in situ |
| LIS | laboratory information system; lateral intercellular space; left intercostal space; library informat... |
| TDLU | terminal ductal lobular unit |
| CLH | Chronic Lobular Hepatitis |
|---|---|
| ILC | Infiltrating lobular carcinoma |
| ILC | Invasive lobular carcinoma |
| LCIS | Lobular carcinoma in situ |
| ALH | atypical lobular hyperplasia |
| lobular neoplasia | <tumour> Carcinoma of the breast in which small tumour cells fill preexisting acini within lobules, without invading the surrounding stroma. Synonym: lobular carcinoma in situ, lobular neoplasia. (05 Mar 2000) |
|---|
| carcinoma, lobular | A infiltrating (invasive) breast cancer, relatively uncommon, accounting for only 5%-10% of breast tumours in most series. It is often an area of ill-defined thickening in the breast, in contrast to the dominant lump characteristic of ductal carcinoma. It is typically composed of small cells in a linear arrangement with a tendency to grow around ducts and lobules. There is likelihood of axillary nodal involvement with metastasis to meningeal and serosal surfaces. (12 Dec 1998) |
|---|---|
| neoplasms, ductal, lobular, and medullary | Neoplasms, usually carcinoma, located within the centre of an organ or within small lobes, and in the case of the breast, intraductally. The emphasis of the name is on the location of the neoplastic tissue rather than on its histological type. most cancers of this type are located in the breast. (12 Dec 1998) |
| noninfiltrating lobular carcinoma | <tumour> Carcinoma of the breast in which small tumour cells fill preexisting acini within lobules, without invading the surrounding stroma. Synonym: lobular carcinoma in situ, lobular neoplasia. (05 Mar 2000) |
| lobular | <anatomy> Pertaining to the part of the breast that is furthest from the nipple, the lobes. (09 Oct 1997) |
| lobular carcinoma | <tumour> A form of adenocarcinoma, especially of the breast, where lobular carcinoma is less common than ductal carcinoma and usually is composed of small cells. (05 Mar 2000) |
| lobular carcinoma in situ | <tumour> Carcinoma of the breast in which small tumour cells fill preexisting acini within lobules, without invading the surrounding stroma. Synonym: lobular carcinoma in situ, lobular neoplasia. (05 Mar 2000) |
| lobular glomerulonephritis | <pathology> A kidney disorder which results in kidney dysfunction. Inflammation of the glomeruli result from an abnormal immune response and the deposition of antibodies within the kidney (glomerulus) ultrastructure. Membranoproliferative glomerulonephritis has been divided into two different types in the basis of where the antibodies are deposited in the glomerulus. MPGN type I, the more common type, deposits antibodies in the subendothelial layer of the basement membrane, whereas type II deposits antibodies in the bottom layer of the basement membrane. Symptoms include cloudy urine (pyuria), decreased urine output, swelling and hypertension. This disorder often results in end-stage renal disease. Acronym: MPGN (26 Mar 1998) |
| cervical intraepithelial neoplasia | A term which describes precancerous changes to the epithelial cells lining the cervix. The diagnosis is made from the microscopic examination of a PAP smear acquired tissue specimen. Less than 5% of all PAP smears will show cervical dysplasia. The peak incidence is in women 25 to 35 years of age. Risk factors include multiple sexual partners, early onset of sexual activity (less than 18), early childbearing (less than 16) and past medical history of a sexually transmitted disease (for example genital warts, genital herpes, HIV infection). Treatment is based on the degree of dysplasia present, as judged by a pathologist. Treatments include cryotherapy and conisation. Origin: Gr. Plassein = to form (27 Sep 1997) |
| multiple endocrine neoplasia | (type I) This is a hereditary disorder in which two or more of the following glands: parathyroid, pancreas, pituitary, adrenals or thyroid develop hyperplasia or a tumour. (type II) This is a hereditary disorder in which two or more of the following glands: thyroid, adrenal or parathyroid, develop overgrowth (hyperplasia) or malignant cells (cancer). The underlying cause is genetic and a positive family history for this illness is a risk factor. Incidence: approximately 3 in 100,000 people in the general population. Origin: Gr. Plassein = to form (27 Sep 1997) |
| multiple endocrine neoplasia 1 | <radiology> Multiple endrocrine neoplasia syndrome three P's. Pituitary adenoma, 65% can develop Cushing's, acromegaly, prolactinoma, parathyroid hyperplasia / adenoma, 88% can develop hyper-PTH pancreatic isleT-cell tumour, gastrinoma (Z-E) most common, 50% of Z-E can develop MEN-1, inconstant features: bronchial/intestinal carcinoid, thyroid adenoma, adrenal cortical tumour, lipoma, thymoma tissue expression Primary hyperparathyroidism (90%), Gastrinoma (30%), Prolactinoma (15%), Other (10%). Synonym: Wermer syndrome (12 Dec 1998) |
| multiple endocrine neoplasia 2 | <radiology> Multiple endocrine neoplasia syndrome, medullary thyroid carcinoma, usually multifocal; metastasis to local nodes, lung, liver, usually calcify in liver, pheochromocytoma, almost always bilateral, parathyroid hyperplasia, may be secondary to calcitonin secreted by medullary thyroid carcinoma inconstant feature: adrenal cortical hyperplasia Synonym: Sipple syndrome (12 Dec 1998) |
| multiple endocrine neoplasia 3 | <radiology> Multiple endocrine neoplasia syndrome (type 2B, type 3), medullary thyroid carcinoma, pheochromocytoma, marfanoid habitus (Cf: Marfan syndrome), mucosal neuromas, neurofibromas, ganglioneuromatosis coli More info: MEN syndrome 2B Synonym: Schimke, marfanoid syndrome (12 Dec 1998) |
| multiple endocrine neoplasia type 1 | A rare syndrome characterised by hyperplasia and/or neoplasms of the pituitary, parathyroid glands, and pancreatic islets. Hyperparathyroidism occurs in 90% of the cases and is usually the first manifestation of the syndrome. The most frequent pancreatic manifestation is gastrinoma typically leading to zollinger-ellison syndrome. The appearance of this condition has been limited to the loss of allelic heterozygosity at the 11q13 locus on the long arm of chromosome 11. Patients overall exhibit long survival times. Chemotherapy is rare and surgical management is generally dependent on the genetic expression in individual patients. (12 Dec 1998) |
| multiple endocrine neoplasia type 2 | <syndrome> This is a hereditary disorder in which two or more of the following glands: thyroid, adrenal or parathyroid, develop overgrowth (hyperplasia) or malignant cells (cancer). The underlying cause is genetic and a positive family history for this illness is a risk factor. Incidence: approximately 3 in 100,000 people in the general population. (27 Sep 1997) |
| multiple endocrine neoplasia type 2a | A type of multiple endocrine neoplasia characterised by a virtually 100% incidence of medullary thyroid carcinoma, a 50% incidence of pheochromocytoma, and a lesser incidence of parathyroid adenomas associated with hyperparathyroidism. The condition is always transmitted through autosomal dominant inheritance. Genetic testing can identify individuals with the trait in early infancy. Treatment is usually excision of the enlarged parathyroid glands. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|